NasdaqGS:BNTXBiotechs
How Investors Are Reacting To BioNTech (BNTX) Expanded Global Patent Suits Targeting Its mRNA COVID-19 Vaccines
In July 2026, Arbutus Biopharma and Genevant Sciences filed new international patent infringement lawsuits against Pfizer, BioNTech and affiliates over lipid nanoparticle technology used in mRNA COVID-19 vaccines, seeking monetary relief and permanent injunctions across Canada and numerous European countries, expanding earlier U.S. legal actions.
These expanded legal claims introduce additional uncertainty around BioNTech’s mRNA platform and COVID-19 vaccine franchise at the same time the...